Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | CYP2A13 | Q16696 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL465943 | 0.84 | HRH3 (0.38) | SMN1; SMN2CXCR4HRH3ALDH1A1HSD17B10 | |
| SCHEMBL15008947 | 0.82 | HRH3 (0.41) | SMN1; SMN2HRH3ALDH1A1HSD17B10MEN1 | |
| SCHEMBL27984313 | 0.81 | ALDH1A1 (0.41) | SMN1; SMN2NPC1RAB9AALDH1A1ALOX15 | |
| SCHEMBL6165901 | 0.81 | POLB (0.43) | NPC1RAB9ACYP2A13ALDH1A1 | |
| SCHEMBL6168432 | 0.79 | CXCR4 (0.43) | CXCR4HRH3ALDH1A1MEN1KMT2A | |
| SCHEMBL2444704 | 0.73 | MAPT (0.43) | SMN1; SMN2HTTALDH1A1KMT2AMAPT | |
| SCHEMBL6164716 | 0.70 | CXCR4 (0.56) | SMN1; SMN2CXCR4NPC1RAB9AHTT | |
| SCHEMBL743040 | 0.70 | SMN1; SMN2 (0.53) | SMN1; SMN2CXCR4NPC1RAB9AHTT | |
| SCHEMBL6167381 | 0.69 | CXCR4 (0.50) | SMN1; SMN2CXCR4NPC1RAB9AHTT | |
| SCHEMBL13551047 | 0.69 | SMN1; SMN2 (0.69) | SMN1; SMN2CXCR4NPC1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3072890-B1 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | MEI PHARMA INC (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-3072890-A1 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | MEI Pharma, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| US-8486939-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | PATHWAY THERAPEUTICS INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2532659-A1 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | Pathway Therapeutics, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-2451802-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | Pathway Therapeutics, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20110009405-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2011-01-13 | — | — | US | disclosed |
| WO-2011005119-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2011-01-13 | — | — | WO | disclosed |
| EP-1417177-A4 | ACYLSEMICARBAZIDES AS CYCLIN DEPENDENT KINASE INHIBITORS USEFUL AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1417177-A2 | ACYLSEMICARBAZIDES AS CYCLIN DEPENDENT KINASE INHIBITORS USEFUL AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS | Bristol-Myers Squibb Pharma Company (US) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003007883-A2 | ACYLSEMICARBAZIDES AS CYCLIN DEPENDENT KINASE INHIBITORS USEFUL AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2003-01-30 | — | — | WO | disclosed |
| EP-1071668-A1 | 5-AMINOINDENO(1,2-C)PYRAZOL-4-ONES AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS | Du Pont Pharmaceuticals Company (US) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999054308-A1 | 5-AMINOINDENO(1,2-C)PYRAZOL-4-ONES AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009405-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | TYMP, TYMS, CCNI | SMN1; SMN2 3760/4885CXCR4 1790/4885NPC1 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.